Group Administrators Office
Spring Meeting Friday Highlights
Friday, May 2, 2014
4:30 - 6:00 pm
Special Plenary Session
Back by popular demand!! Building on the success of last year, the Canadian Cancer Trials Group will be showcasing three Canadian Cancer Trials Group trials and a general research study.
Dr. Peter Ellis will be presenting:
BR.26: A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Dr. Patricia Tang will be presenting:
Estimation of Cost Avoidance in Canadian Cancer Trials Group Phase III Clinical Trials
Dr. Hal Hirte will be presenting:
IND.206: A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours
Dr. Michael Crump will be presenting:
LY.12: Randomized Phase III Study of Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas - Part 2
Canadian Cancer Trials Group Awards Ceremony
Following the Special Plenary Session, the Canadian Cancer Trials Group will be hosting the 2014 Recognition Awards Ceremony. In addition to the 2014 IND awards (the Early Drug Development Team Award and the Elizabeth Eisenhauer Early Drug Development Young Investigator Award) introduced last year for the first time, three NEW awards will be presented this year - the Ralph Meyer Phase III Program Young Investigator Award, the Phase III Program Team Award, and the Joseph Pater Founder's Award for Excellence in Clinical Trials Research. Both Ralph and Joe will be in attendance to make the presentations.
Here are the 2014 awardees:
Joseph Pater Founder's Award for Excellence in Clinical Trials Research, which recognizes an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
2014 Recipient - Dr. Vivien Bramwell
Ralph Meyer Phase III Young Investigator Award, which recognizes an exceptional MD, fellow, or PhD, within 3 years of certification / first faculty appointment or current fellow who has either spent time at Canadian Cancer Trials Group?s Central Office, worked on Phase III projects with Disease Site Committees / Endpoint Committees / Working Groups, or who has contributed significantly to the conduct of a Phase III trial at a centre.
2014 Recipient - Dr. Annette Hay
Elizabeth Eisenhauer Early Drug Development Young Investigator Award, which is presented annually to an exceptional MD, fellow, or PhD, within 3 years of certification / first faculty appointment, or current fellow who has either spent time at Canadian Cancer Trials Group's Central Office, worked on projects with the Investigational New Drug Program, or who has contributed significantly to the conduct of an IND trial at a centre.
2014 Recipient - Dr. Daniel Renouf
Early Drug Development Team Award presented to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in any Canadian Cancer Trials Group IND clinical trial to acknowledge their efforts and dedication to the success of clinical trials.
Phase III Program Team Award, Awarded to individual trial teams from Canadian member centres to acknowledge their efforts and dedication to the success of clinical trials.
Mix, Mingle and Martinis Reception
Following the Plenary Session and Awards Ceremony, we invite all attendees to the "Mix, Mingle and Martinis Reception" where we can all enjoy an array of appetizers and refreshments and celebrate everyone's hard work. A cash bar will be available.